Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups

• Published in: Blood 2021-11, Vol.138 (Supplement 1), p.694-694
• Main Authors: Maiti, Abhishek, DiNardo, Courtney D., Rausch, Caitlin R., Pemmaraju, Naveen, Garcia-Manero, Guillermo, Ohanian, Maro, Daver, Naval, Issa, Ghayas C., Borthakur, Gautam, Ravandi, Farhad, Alvarado, Yesid, Kadia, Tapan M., Jabbour, Elias J., Short, Nicholas J., Montalban-Bravo, Guillermo, Jain, Nitin, Kornblau, Steven M., Masarova, Lucia, Wierda, William G., Sasaki, Koji, Takahashi, Koichi, Yilmaz, Musa, Burger, Jan A., Estrov, Zeev E., Verstovsek, Srdan, Andreeff, Michael, Bose, Prithviraj, Ferrajoli, Alessandra, Thompson, Philip A., Montalbano, Kathryn, Vaughan, Kenneth, Bivins, Carol A., Pierce, Sherry A., Qiao, Wei, Ning, Jing, Welch, John S., Kantarjian, Hagop, Konopleva, Marina
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2021-153227

▪ Background: DEC10-VEN is an effective regimen and offers better outcomes compared to intensive chemotherapy in older pts with newly diagnosed (ND) or relapsed/refractory (R/R) AML (Maiti. Am J Hematol 2021; Maiti. Cancer 2021). We report long term outcomes in major genomic subgroups. Methods: Pts received decitabine 20 mg/m 2 on D1-10 until CR/CRi, followed by 5-day cycles. VEN dose was 400 mg daily but held on C1D21 if D21 bone marrow (BM) had ≤5% blasts. VEN could be reduced to